Corvus Pharmaceuticals, Inc. (CRVS)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
CRVS Insider Trading Activity
CRVS Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $1,034,624 | 2 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| MILLER RICHARD A MD | President and CEO | 1 | $1,000,000 | 0 | $0 | $1,000,000 |
| Jones William Benton | See Remarks | 1 | $34,624 | 0 | $0 | $34,624 |
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Insider Activity of Corvus Pharmaceuticals, Inc.
Over the last 12 months, insiders at Corvus Pharmaceuticals, Inc. have bought $1.03M and sold $0 worth of Corvus Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Corvus Pharmaceuticals, Inc. have bought $2.14M and sold $23.37M worth of stock each year.
Highest buying activity among insiders over the last 12 months: MILLER RICHARD A MD (President and CEO) — $1,000,000. Jones William Benton (See Remarks) — $34,624.
The last purchase of 577,634 shares for transaction amount of $1,000,000 was made by MILLER RICHARD A MD (President and CEO) on 2024‑05‑06.
List of Insider Buy and Sell Transactions, Corvus Pharmaceuticals, Inc.
| 2024-05-06 | MILLER RICHARD A MD | President and CEO | 577,634 1.0676% | $1.73 | $1,000,000 | +142.41% | ||
| 2024-05-06 | Jones William Benton | See Remarks | 20,000 0.037% | $1.73 | $34,624 | +142.41% | ||
| 2023-05-15 | Grais Linda | director | 10,000 0.0202% | $2.45 | $24,500 | -22.88% | ||
| 2022-12-20 | Jones William Benton | See Remarks | 20,000 0.0435% | $0.79 | $15,800 | +85.90% | ||
| 2022-12-14 | MILLER RICHARD A MD | President and CEO | 10,000 0.021% | $0.78 | $7,812 | +77.50% | ||
| 2022-12-14 | LEA LEIV | Chief Financial Officer | 4,000 0.009% | $0.84 | $3,364 | +77.50% | ||
| 2022-12-13 | MILLER RICHARD A MD | President and CEO | 50,000 0.1031% | $0.74 | $37,015 | +84.18% | ||
| 2022-12-13 | LEA LEIV | Chief Financial Officer | 30,000 0.0621% | $0.74 | $22,275 | +84.18% | ||
| 2022-06-24 | MILLER RICHARD A MD | President and CEO | 5,000 0.0123% | $1.00 | $4,985 | +4.60% | ||
| 2022-06-02 | MILLER RICHARD A MD | President and CEO | 890 0.002% | $1.01 | $899 | -7.89% | ||
| 2022-03-31 | MILLER RICHARD A MD | President and CEO | 15,000 0.0321% | $1.64 | $24,534 | -44.51% | ||
| 2022-03-16 | LEA LEIV | Chief Financial Officer | 13,878 0.0307% | $1.65 | $22,899 | -42.38% | ||
| 2022-03-15 | MILLER RICHARD A MD | President and CEO | 5,000 0.0117% | $1.59 | $7,950 | -36.44% | ||
| 2021-10-01 | Sale | EcoR1 Capital, LLC | 10 percent owner | 2M 4.4342% | $4.96 | $9.93M | -67.36% | |
| 2021-09-30 | Sale | EcoR1 Capital, LLC | 10 percent owner | 3M 6.7156% | $5.04 | $15.13M | -67.46% | |
| 2021-09-20 | Sale | Thompson Peter A. | 1.11M 2.4922% | $6.09 | $6.76M | -73.58% | ||
| 2021-09-20 | Sale | ORBIMED ADVISORS LLC | 1.11M 2.4922% | $6.09 | $6.76M | -73.58% | ||
| 2021-08-20 | MILLER RICHARD A MD | President and CEO | 10,000 0.0229% | $1.93 | $19,254 | -5.76% | ||
| 2021-05-04 | MILLER RICHARD A MD | President and CEO | 35,714 0.0833% | $2.80 | $99,999 | -13.38% | ||
| 2021-02-17 | Thompson Peter A. | 1.29M 3.6216% | $3.50 | $4.5M | -23.75% |
Insider Historical Profitability
| MILLER RICHARD A MD | President and CEO | 577634 0.8989% | $1.95M | 29 | 0 | +5.49% |
| Jones William Benton | See Remarks | 153773 0.2393% | $518,215.01 | 2 | 0 | +85.9% |
| ORBIMED ADVISORS LLC | 6943654 10.806% | $23.4M | 19 | 1 | +4.76% | |
| Thompson Peter A. | 6943654 10.806% | $23.4M | 19 | 1 | +4.76% | |
| Novo Holdings A/S | 10 percent owner | 1389498 2.1624% | $4.68M | 3 | 5 | +12.06% |
| ADAMS STREET PARTNERS LLC | 10 percent owner | 236128 0.3675% | $795,751.36 | 2 | 0 | <0.0001% |
| Gould Terry P | 236128 0.3675% | $795,751.36 | 2 | 0 | <0.0001% | |
| LEA LEIV | Chief Financial Officer | 133238 0.2074% | $449,012.06 | 6 | 0 | +20.44% |
| EcoR1 Capital, LLC | 10 percent owner | 81077 0.1262% | $273,229.49 | 0 | 2 | |
| Grais Linda | director | 10000 0.0156% | $33,700.00 | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$7,201,783 | 88 | -8.61% | $225.73M | |
Corvus Pharmaceuticals, Inc. (CRVS) | $99,438,720 | 81 | 6.74% | $216.55M |
$48,218,096 | 42 | 0.89% | $192.64M | |
$17,983,739 | 41 | 102.87% | $228.84M | |
$2,545,071 | 34 | 16.59% | $241.88M | |
$18,554,304 | 31 | -11.72% | $236.38M | |
$41,069,367 | 23 | 54.64% | $224.28M | |
$3,513,995 | 18 | -13.04% | $244.61M | |
$46,858,891 | 18 | -11.61% | $237.84M | |
$2,081,205 | 17 | -20.90% | $197.04M | |
$2,484,989 | 17 | -17.86% | $211.39M | |
$4,701,608 | 14 | -4.34% | $201.32M | |
$11,230,365 | 11 | -45.81% | $204.2M | |
$145,296,407 | 8 | -0.98% | $206.47M | |
$335,001 | 6 | -23.71% | $239.92M | |
$55,858,393 | 5 | 14.12% | $207.29M | |
$356,211 | 4 | 32.45% | $193.97M | |
$4,888,000 | 3 | -20.50% | $215.78M | |
$149,309 | 3 | 6.07% | $242.14M |
CRVS Institutional Investors: Active Positions
| Increased Positions | 63 | +118.87% | 12M | +42.35% |
| Decreased Positions | 21 | -39.62% | 4M | -12.96% |
| New Positions | 34 | New | 7M | New |
| Sold Out Positions | 9 | Sold Out | 600,212 | Sold Out |
| Total Postitions | 95 | +79.25% | 38M | +29.4% |
CRVS Ownership Change vs Market
Institutional Investor Ownership
| Orbimed Advisors Llc | $29,927.00 | 10.85% | 6.94M | 0 | 0% | 2024-12-31 |
| Samlyn Capital, Llc | $28,735.00 | 10.42% | 6.67M | +2M | +47.17% | 2024-12-31 |
| Adams Street Partners Llc | $14,118.00 | 5.12% | 3.28M | 0 | 0% | 2024-12-31 |
| Point72 Asset Management, L.P. | $13,059.00 | 4.73% | 3.03M | -3M | -45.53% | 2024-12-31 |
| Rtw Investments, Lp | $11,549.00 | 4.19% | 2.68M | +3M | New | 2024-12-31 |
| Vanguard Group Inc | $10,579.00 | 3.84% | 2.45M | +33,977 | +1.4% | 2024-12-31 |
| Vivo Capital, Llc | $9,631.00 | 3.49% | 2.23M | +737,298 | +49.24% | 2024-12-31 |
| Foresite Capital Management Vi Llc | $6,815.00 | 2.47% | 1.58M | +2M | New | 2024-12-31 |
| Blackrock, Inc. | $4,624.00 | 1.68% | 1.07M | +469,064 | +77.67% | 2024-12-31 |
| Susquehanna International Group, Llp | $4,375.00 | 1.59% | 1.02M | +796,121 | +363.59% | 2024-12-31 |